We have a two part mini-series this week exploring an approach on how to boost T cells in cold tumours. There are a number of different ways to do this, including adding them ex vivo such as via CAR T cell therapies, although this technique has yet to yield durable benefit in solid tumours.
So how else can it be done?
We’ve discussed immune agonists, oncolytic viruses and cancer vaccines in the past so now it’s time for something different…
In Part 1 of the series today, we explore the science behind the technology and some of the early clinical data that was recently presented at medical meetings.
In Part 2 tomorrow, we have not one but three, different voices exploring some researchers thoughts on where the approach might go.
It should make for interesting reading!